Hypera is offloading a basket of brands it recently acquired from Takeda which are sold primarily in Mexico to São Paulo-based Eurofarma. 

Company’s Phase III program is attempting to replicate Phase II efficacy data showing superiority for curing Clostridium difficile infections and preventing recurrence, while also compiling health economics data.

Amicus announced its ambitions in gene therapy last year, recently purchased Celenex and 10 pipeline candidates, and now partners with Penn on gene therapies. Celltrion is collaborating with Emory in atherosclerosis therapies.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2017.